Association of tumour mutational burden (TMB) with outcomes in stage IIIA(N2) non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemotherapy and durvalumab: prospective analysis of the multicenter single-arm phase II trial SAKK16/14

被引：0
|
作者：
Alborelli, I [1 ]
Jermann, P. M. [2 ]
Leonards, K. [2 ]
Manzo, M. [2 ]
Keller, E. [2 ]
Zippelius, A. [1 ,3 ]
Eboulet, E., I [4 ]
Betticher, D. [5 ]
Frueh, M. [6 ]
Britschgi, C. [7 ]
Peters, S. [8 ]
Mark, M. [9 ]
Ochsenbein, A. F. [10 ]
Janthur, W. -D [11 ]
Waibel, C. [12 ]
Mach, N. [13 ]
Froesch, P. [14 ]
Pless, M. [15 ]
Prince, Savic S. [2 ]
Rothschild, S. [1 ]
机构：
[1] Univ Spital Basel, Med Onkol, Basel, Switzerland
[2] Univ Spital Basel, Inst Pathol, Basel, Switzerland
[3] Univ Spital Basel, Dept Biomed Lab Tumorimmunol, Basel, Switzerland
[4] Schweizer Arbeitsgemeinschaft Klin Krebsforsch SA, Bern, Switzerland
[5] HFR Fribourg Hop Fribourgeois, Med Onkol, Fribourg, Switzerland
[6] Kantonsspital St Gallen, Onkol Hamatol, St Gallen, Switzerland
[7] Univ Spital Zurich, Med Onkol & Hamatol, Zurich, Switzerland
[8] Ctr Hosp Univ Vaudois CHUV, Med Onkol, Lausanne, Switzerland
[9] Kantonsspital Graubunden, Onkol Hamatol, Chur, Switzerland
[10] Inselspital Bern, Med Onkol, Bern, Switzerland
[11] Kantonsspital Aarau, Onkol Hamatol & Transfus Med, Aarau, Switzerland
[12] Kantonsspital Baden, Onkol Hamatol, Baden, Switzerland
[13] Hop Univ Geneve, Med Onkol, Geneva, Switzerland
[14] Ist Oncol Svizzera Italiana IOSI, Bellinzona, Switzerland
[15] Kantonsspital Winterthur, Med Onkol, Winterthur, Switzerland
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ep658
引用
收藏
页码：174 / 175
页数：2
相关论文
共 50 条
  • [1] Association of tumour mutational burden with outcomes in patients with stage IIIA-NSCLC treated with neoadjuvant chemotherapy and durvalumab (SAKK16/14)
    Alborelli, I.
    Rothschild, S.
    Jermann, P.
    Leonards, K.
    Manzo, M.
    Keller, E.
    Zippelius, A.
    Eboulet, E. I.
    Betticher, D.
    Fruh, M.
    Britschgi, C.
    Peters, S.
    Mark, M.
    Ochsenbein, A. F.
    Janthur, W. -D.
    Waibel, C.
    Mach, N.
    Frosch, P.
    Pless, M.
    Prince, S. Savic
    SWISS MEDICAL WEEKLY, 2021, 151 : 15 - 15
  • [2] SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients with Stage IIIA(N2) NSCLC - A Multicenter Single-Arm Phase II Trial
    Rothschild, S.
    Zippelius, A.
    Savic, S.
    Gonzalez, M.
    Weder, W.
    Xyrafas, A.
    Rusterholz, C.
    Pless, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1025 - S1025
  • [3] SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial
    Rothschild, Sacha, I
    Zippelius, Alfred
    Eboulet, Eric, I
    Prince, Spasenija Savic
    Betticher, Daniel
    Bettini, Adrienne
    Frueh, Martin
    Joerger, Markus
    Lardinois, Didier
    Gelpke, Hans
    Mauti, Laetitia A.
    Britschgi, Christian
    Weder, Walter
    Peters, Solange
    Mark, Michael
    Cathomas, Richard
    Ochsenbein, Adrian F.
    Janthur, Wolf-Dieter
    Waibel, Christine
    Mach, Nicolas
    Froesch, Patrizia
    Buess, Martin
    Bohanes, Pierre
    Godar, Gilles
    Rusterholz, Corinne
    Gonzalez, Michel
    Pless, Miklos
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (26) : 2872 - +
  • [4] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA (N2) non-small cell lung cancer (NSCLC) - A multicenter single-arm phase II trial
    Rothschild, S. I.
    Zippelius, A.
    Eboulet, E. I.
    Prince, S. Savic
    Betticher, D.
    Bettini, A.
    Fruh, M.
    Joerger, M.
    Britschgi, C.
    Peters, S.
    Mark, M. T.
    Ochsenbein, A. F.
    Janthur, W-D.
    Waibel, C.
    Mach, N.
    Gonzalez, M.
    Froesch, P. R.
    Godar, G.
    Rusterholz, C.
    Pless, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S803 - S804
  • [5] SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)-A multicenter single-arm phase II trial.
    Rothschild, Sacha
    Zippelius, Alfred
    Eboulet, Eric, I
    Savic, Spasenija
    Betticher, Daniel C.
    Bettini, Adrienne
    Frueh, Martin
    Joerger, Markus
    Britschgi, Christian
    Peters, Solange
    Mark, Michael Thomas
    Ochsenbein, Adrian
    Janthur, Wolf Dieter
    Waibel, Christine
    Mach, Nicolas
    Gonzalez, Michel
    Froesch, Patrizia
    Godar, Gilles
    Rusterholz, Corinne
    Pless, Miklos
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC): A multicenter single-arm phase II trial
    Rothschild, S. I.
    Zippelius, A.
    Prince, S. Savic
    Gonzalez, M.
    Weder, W.
    Xyrafas, A.
    Rusterholz, C.
    Pless, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S70 - S70
  • [7] SAKK 16/14: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)-A multicenter single-arm phase II trial
    Rothschild, Sacha
    Zippelius, Alfred
    Savic, Spasenija
    Gonzalez, Michel
    Weder, Walter
    Xyrafas, Alexandros
    Rusterholz, Corinne
    Pless, Miklos
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] SAKK 16/14-anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage ILIA (N2) non-small cell lung cancer (NSCLC). A multicenter single-arm phase II trial
    Rothschild, S. I.
    Zippelius, A.
    Prince, S. Savic
    Gonzalez, M.
    Weder, W.
    Xyrafas, A.
    Rusterholz, C.
    Pless, M.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S112 - S112
  • [9] SAKK 16114: Anti-PD-L1 antibody durvalumab (MEDI4736) in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)-A multicenter single-arm phase II trial.
    Rothschild, Sacha
    Zippelius, Alfred
    Savic, Spasenija
    Gonzalez, Michel
    Weder, Walter
    Xyrafas, Alexandros
    Rusterholz, Corinne
    Pless, Miklos
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] SAKK 16/14-Perioperative Anti-PD-L1 Antibody Durvalumab in Patients with Stage IIIA(N2) Non-Small Cell Lung Cancer (NSCLC)
    Rothschild, S.
    Zippelius, A.
    Savic, S.
    Gonzalez, M.
    Weder, W.
    Xyrafas, A.
    Rusterholz, C.
    Pless, M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2149 - S2149
12345